NORD Senior VP Elected to USP Expert Committee
WASHINGTON DC---J. Russell Teagarden of the National Organization for Rare Disorders (NORD) has been elected to the Therapeutic Information and Formulary Support (TIFS) Expert Committee of the U.S. Pharmacopeial Convention (USP), a scientific nonprofit organization that sets standards for drug quality and related practices applied in the U.S. and many other countries around the world.
The committee, whose members are selected by the USP Council of Experts Executive Committee, will focus on the development of formulary support standards, such as the USP Medicare Model Guidelines, and standards associated with therapeutic information and decision support for practitioner-oriented topics. This would include topics such as drug shortages, biologic medicines, and personalized medicine/diagnostics.
"These are all important topics in the rare disease community, and we are pleased that a NORD representative has been selected to be part of this influential group," said NORD President and CEO Peter L. Saltonstall.
As Senior Vice President of Medical and Scientific Affairs at NORD, Teagarden is responsible for the medical and scientific dimensions of research, programming, and policy initiatives. He joined NORD after 19 years at Medco Health Solutions where he was chiefly involved in drug technology assessment, coverage policy, formulary development, clinical programming, research, and clinical oversight.
Prior to joining Medco, he practiced as a clinical pharmacist in critical care and drug information in the Chicago teaching hospital community. Teagarden has a BS in pharmacy, MA in research methods, and doctorate in medical humanities.